{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T23:57:56Z","timestamp":1790467076608,"version":"4.1.0"},"reference-count":0,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pharmacol"],"published-print":{"date-parts":[[2021]]},"DOI":"10.4103\/ijp.ijp_615_20","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T15:41:58Z","timestamp":1716478918000},"page":"226","source":"Crossref","is-referenced-by-count":14,"title":["Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors"],"prefix":"10.4103","volume":"53","author":[{"given":"Erkan","family":"Cure","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adem","family":"Kucuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MedineCumhur","family":"Cure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:56:57Z","timestamp":1787065017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.IJP_615_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"alternative-id":["318975"],"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_615_20","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}